MINERALYS THERAPEUTICS INC
MLYSNASDAQ🏆 #1711 by market capEarnings Aug 12US Equity
$27.54▲ $0.21 (+0.77%)
Live1h▲ 0.4%
24h▲ 0.8%
7d▲ 2.6%
14d▲ 4.6%
30d▼ 0.2%
1y▲ 103.7%
🏦Market Cap
$2.43B
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
54
Weak
Trading Snapshot
- Day Range
- $27.15 – $27.90
- 52-Week Range
- $12.59 – $47.65
- Volume
- $2.55B
- Avg Volume
- $2.99B
- Shares Outstanding
- 88.2M
- Next Earnings
- Oct 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $209M
- Last Q Revenue
- $55M
- P/E Ratio
- -6.5
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-4.13
- Dividend Yield
- 0.00%
Why Investors Own MLYS
- ✓High-growth profile — revenue up +24.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 25% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$209M▲ +20.5% YoY
Gross Margin (TTM)
25.1%▲ +3.4% YoY
Operating Income (TTM)
$19M▲ +20.5% YoY
Free Cash Flow (TTM)
$23M▲ +20.5% YoY
About MINERALYS THERAPEUTICS INC
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
54/100
Analyst Ratings
ⓘConsensus
Buy
16 analysts
Strong Buy5
Buy9
Hold2
Sell0
Strong Sell0
Ratings as of Aug 2026